RATIONALE: Gestational and maternal factors such as mode of delivery and duration of pregnancy have been linked to development of atopy. In this study we examined the link between pregnancy related variables with food allergen profile, and Food allergy (FA)-related comorbid conditions. METHODS: We completed a prospective cohort study of children with (FA) at a tertiary care center in Chicago. Mothers completed a questionnaire about their pregnancy and delivery of their child with FA. We analyzed these variables in association with demographics, age of onset of FA, atopic and non-atopic comorbidities, and type and number of food allergens. RESULTS: The cohort included 195 children with FA. There was a significant association between a shorter duration of pregnancy and history of atopic dermatitis (AD) in these children (mean6 SD of 37.563.6weeks vs. 38.262.8 weeks ; p50.01 in children with and without AD). Mode of delivery was associated with milk allergy; 26.8% of milk allergic children vs. 19.6% of non-milk allergic children were born by Cesarean-section (Csection); p50.04. GERD was associated with C-section; 25.4% of children with GERD vs.11.1% of those without GERD were born by Cesareansection; p50.001. CONCLUSIONS: C-section was associated with milk allergy and GERD, while duration of pregnancy was linked to comorbid AD. These observations might be due to a causative link of gestational/delivery factors related to FA and AD, or to a possible underlying cause resulting in shorter gestation time and need for Cesarean-section as well as the predisposition to atopy in these children. 
METHODS:
Sixty healthy adults with seasonal allergies were enrolled (12/cohort). In Part 1, Cohorts 1-4 received a single dose (3 mg or 6 mg) of Epinephrine NS AQ and HA in assigned sequence; Cohort 5 received a single dose of EpiPen IM 0.3 mg under fasted conditions. In Part 2, the study was repeated with predosing allergen challenge. Epinephrine plasma concentrations for 6 mg NS formulations were analyzed to determine epinephrine pharmacokinetics. Safety assessments included physical and nasal exams, adverse events (AEs), vital signs, ECGs, and clinical laboratory and olfactory tests for both 3 and 6 mg NS doses. RESULTS: Epinephrine was rapidly absorbed following single 6 mg AQ and HA doses vs. EpiPen, with epinephrine plasma concentrations above 100 pg/mL within 5 minutes and median t max within 5-16 minutes for AQ, 3-10 minutes for HA, and 5 minutes for EpiPen. Compared to EpiPen, epinephrine exposure was 73-126% following 6 mg HA, and 35-86% following 6 mg AQ. Allergen challenge mainly impacted epinephrine absorption, with C max increased 1.72-fold for AQ and 1.43-fold for HA, with minor change in AUC for AQ or HA; EpiPen exposure was unaffected.
Most AEs reported were mild; none were serious. The most common AE was nasal discomfort. CONCLUSIONS: Epinephrine NS HA demonstrated good absorption to reach desired exposure rapidly and was comparable to EpiPen. Both formulations were safe and well tolerated.
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The Brutons tyrosine kinase inhibitor acalabrutinib protects from anaphylaxis in a humanized mouse model Melanie C. Dispenza, MD PhD, Rebecca A. Krier-Burris, and Bruce S. Bochner, MD FAAAAI; Northwestern University, Chicago, IL. RATIONALE: There is an unmet need for therapies that can prevent anaphylaxis. Acalabrutinib is a well-tolerated, FDA approved drug for leukemia that targets Bruton's tyrosine kinase (BTK), an enzyme also thought to be essential for IgE receptor signaling in human mast cells and basophils. We tested the hypothesis that acalabrutinib administration would prevent anaphylaxis in a humanized mouse model. METHODS: NSG-SGM3 mice were engrafted with human CD34+ cells at age 3-4 weeks. 16 weeks after engraftment, passive systemic anaphylaxis (PSA) was induced by intravenous sensitization with human anti-NPIgE and challenge 24 hours later with intravenous injection of NP-BSA. Mice were pre-treated with acalabrutinib or vehicle control via oral gavage prior to challenge. Anaphylactic responses were assessed using core body temperature and clinical scoring. RESULTS: NSG-SGM3 mice engrafted with human CD34+ cells showed good engraftment of human mast cells in addition to excellent PSA responses. Increasing the challenge dose of NP-BSA from 5 to 500 mg resulted in increased severity of anaphylaxis, from mild to fatal responses. Two doses of 15 mg/kg acalabrutinib administered 16 and 4 hours prior to challenge completely mitigated, and 1.5 mg/kg partially mitigated, responses to moderate PSA compared to mice gavaged with vehicle. CONCLUSIONS: NSG-SGM3 humanized mice represent a unique model for the study of anaphylaxis where the severity of response can be controlled by varying the amount of allergen used for challenge. Furthermore, pretreatment with just two doses of acalabrutinib completely prevented PSA in these mice, suggesting that BTK inhibitors may be able to prevent IgE-mediated anaphylaxis in humans.
